Patient motivation for non-persistence with medication impacts self-reported compliance

Main Article Content

Virginia Pascual-Ramos Irazú Contreras-Yáñez Diana Isabel Pérez-Román


1.1 Introduction

In 2004 we initiated an inception cohort of patients with recent-onset rheumatoid arthritis (RA). From 2008 onward, compliance (C) was assessed at fixed intervals, using a questionnaire (CQ) that additionally investigated 15 predefined motivations for non-persistence with therapy (P), and a visual analogue scale (C-VAS, 0-100mm). Objectives were to examine the correlation between the CQ and the C-VAS and to investigate if the selection of patient-independent motivations for non-P predicted better self-reported C.

1.2 Materials and methods

Up to January 2016, the cohort comprised 180 patients with variable follow-up. Each pre-specified motivation for non-P was classified as patient-dependent or patient-independent by 50 patients randomly selected (≥70% agreement). Descriptive statistics and multiple regression analysis were used. Written informed consent was obtained.

1.3 Results

Length of follow-up from 160 patients for which data were completed and analyzed was 6.7±3.4 years; all the patients scored 1516 pairs of CQ and C-VAS. C-VAS significantly correlated with the CQ, r=0.468, p=0.001. Optimal C-VAS cut-off value to predict CQ-compliance was ≤7.5 mm.

During follow-up, there were 670 CQ scored as with non-P among whom, 654 had at least one motivation for non-P selected; of them, 549 CQ (70.2%) corresponded to non-P patients who selected only patient-independent motivations. The selection of exclusively independent motivations for non-P predicted C-VAS and CQ scores. Also, the selection of exclusively independent motivations for non-P predicted compliance either per VAS (OR: 15.6, 95%CI: 5.4-45.3, p≤0.001) or per CQ (OR: 2.25, 95%CI: 1.062-4.664, p=0.034).

1.4 Conclusions

Patient motivation for non-persistence with medication impacts self-reported C.

Article Details

How to Cite
PASCUAL-RAMOS, Virginia; CONTRERAS-YÁÑEZ, Irazú; PÉREZ-ROMÁN, Diana Isabel. Patient motivation for non-persistence with medication impacts self-reported compliance. Medical Research Archives, [S.l.], n. 4, aug. 2016. ISSN 2375-1924. Available at: <>. Date accessed: 16 june 2024.
rheumatoid arthritis, adherence medication, health behavior.
Research Articles


Bellamy N. Critical review of clinical assessment techniques for rheumatoid arthritis trials : new developments. Scan J Rheumatology 1989; 80:3-16.

Clifford S, Barber N, Horne R. Understanding different beliefs held by adherers, unintentional non-adherers and intentional non-adherers: application of the necessity-concerns framework. J Psychosomat Res 2008; 64:41-46.

Contreras-Yáñez I, Cabiedes J†, Villa AR, Rull-Gabayet M, Pascual-Ramos V. Persistence on therapy is a major determinant of patient-, physician- and laboratory- reported outcomes in recent-onset rheumatoid arthritis patients. Clin Exp Rheumatol 2010;28:748-51.

Contreras-Yáñez I, Ponce de León S, Cabiedes J†, Rull-Gabayet M, Pascual-Ramos V. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease modifying antirheumatic drugs. Am J Med Sc 2010; 340(4):282-90.

Grigor C, Capell H, Stirling A. Effect of treatment strategy of tight control for Rheumatoid Arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet 2004; 364 (9430):263-9.

Hill J, Bird H, Johnson S. Effect of patient education on adherence to drug treatment for rheumatoid arthritis : a randomized controlled trial. Ann Rheum Dis 2001 ; 60 :869-75.

Horne R, Weinman J. Patient´s beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999 ; 47 :555-567.

Jing J, Grant ES, Vernon MSO, Shu CL. Factors affecting therapeutic compliance: A review from the patient´s perspective, Ther Clin Risk Manag 2008; 4(1):269-86.

Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE Jr, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care 2002;8:231-40.

Lati C, Guthrie LC, Ward MM. Comparison of the construct validity and sensitivity to change of the visual analogue scale and a modified rating scale as measures of patient global assessment in rheumatoid arthritis. J rheumatol 2010 ; 37(4) :717-22.

Lorish CD, Richards B, Brown S. Missed medication doses in rheumatic arthritis patients: intentional and unintentional reasons. Arthritis Care Res 1989; 2:3-9.

McCormack HM, Horne DJ, Sheater S. Clinical applications of visual analogue scales: a critical review. Psychol Med 1988; 18(4):1007-19.

Mody GM, Cardiel MH. Challenges in the management of rheumatoid arthritis in developing countries. Best Pract Res Clin Rheumatol 2008;22:621-41.

Morrison DP. The Crichton visual analogue scale for the assessment of behavior in teh elderly. Acta Psy Scan 1983 ; 68 :408-13.

Neame R, Hammond A. Beliefs about medications : a questionnaire survey of people with rheumatoid arthitis. Rheumatol 2005 ; 44 :762-67.

Pascual-Ramos V, Contreras-Yáñez I. Motivations for inadequate persistence with disease modifying antirheumatic drugs. The patient´s perspective. BMC Musculoskeletal Disorders 2013;14:336.

Pascual-Ramos V, Contreras-Yáñez I, Villa AR, Cabiedes J†, Rull-Gabayet M. Medication persistence over two years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and disability. Arthritis Res Ther 2009;11(1):R26.

Pasma A, van´t Spijker A, Hazes JMW, Busschbach, Luime JJ. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients : A systematic review. Sem Arthritis Rheum 2013 ; 43 :18-28.

Rampling DJ, Williams RA. Evaluation of group processes using visual analogue scales. Australina and New Zealand J Psych 1977 ; 11 :189-91.

Rosenstock IM, Strecher VJ, Becher MH. Social learning theory and the Health Belief Model. Health Educ Quart 1988 ; 152 :175-83.

Sanderson T, Kirwan J. Patient-reported outcomes of arthritis: time to focus on personal life impact measures? Editorial Arthritis Rheum 2009;61:1-3.

Scheiman-Elazary, Lewei D, Shourt C, Agrawal H, Ellashof D, Cameron-Hay M, et al. The rate of adherence to antiarthritis medications and associated factors among patients with rheumatoid arthritis: A systematic literature review and Metaanalysis. J
Rheumatol 2016; 43(3):512-23.

Scott J, Huskinsson EC. Graphic representation of pain. Pain 1976 ; 2 :175-84.

Van der Bemt BJF, Zwikker HE, VAN DEN Ende C. Medication Adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Exp Rev Clin Immunol 2012; 8(4):337-51.

Van Dulmen S, Sluijs E, VAN Dijk L, De Ridder D, Heerdink R, Bensing J. Patient adherence to medical treatment : a review of reviews. BMC Health Services Research 2007; 7 :55.

Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.

World Health Organization. Adherence to long-term therapies: evidence for action. 2016. [Internet. Accessed June 10, 2016.]. Available from :